Research programme: regenerative therapeutics - La Jolla Pharmaceutical

Drug Profile

Research programme: regenerative therapeutics - La Jolla Pharmaceutical

Alternative Names: LJP-1485; Regenerative Immunophilin Ligands

Latest Information Update: 25 May 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GliaMed
  • Developer La Jolla Pharmaceutical Company
  • Class Small molecules
  • Mechanism of Action Immunophilin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Scars

Most Recent Events

  • 30 Mar 2012 Discontinued - Preclinical for Scars in USA (unspecified route)
  • 06 Apr 2011 Preclinical trials in Scars in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top